Thor Medical and ARTBIO sign supply agreement for Thorium-228

Thor Medical signed a strategic master supply agreement with ARTBIO for a 5-year supply of Thorium-228, with potential revenues of up to NOK 400 million (USD 38 million). The Thorium-228 will be produced at Thor Medical's planned commercial facility at Herøya Industrial Park in Norway, with an investment decision expected in Q1 2025.

“Securing strategic supply agreements are an important prerequisite for a positive investment decision for our planned commercial production plant.”live.euronext.com

• 1 source
• live.euronext.comThor Medical and ARTBIO sign strategic long-term supply agreement for Thorium-228Oct 29, 2024

Summarized from public sources; check the original articles before acting on it.